Showing 1 - 6 of 6
Implicit in the drug-approval process is a trade-off between Type I and Type II error. We explore the application of Bayesian decision analysis (BDA) to minimize the expected cost of drug approval, where relative costs are calibrated using U.S. Burden of Disease Study 2010 data. The results for...
Persistent link: https://www.econbiz.de/10013016659
Persistent link: https://www.econbiz.de/10012668503
Persistent link: https://www.econbiz.de/10012303603
Persistent link: https://www.econbiz.de/10011704723
Persistent link: https://www.econbiz.de/10013539520
Persistent link: https://www.econbiz.de/10014471398